RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $30

Futu NewsJan 7 22:35 · Ratings

BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $22

Futu NewsJan 7 21:35 · Ratings

Express News | Regenxbio Inc : BofA Global Research Cuts Price Objective to $22 From $25

BreakingsJan 7 21:28

Novartis Reports Positive Results for Intrathecal Zolgensma

Seeking AlphaDec 30, 2024 23:58

PepGen Stock Craters 35% on FDA Clinical Hold

Seeking AlphaDec 16, 2024 22:56

RBC Capital Reiterates Outperform on Regenxbio, Maintains $35 Price Target

BenzingaDec 11, 2024 23:54 · Ratings